Magrolimab was the centerpiece of Gilead Sciences Inc's (NASDAQ:GILD) $4.9 billion buyout of Forty Seven Inc in March 2020. Magrolimab is a monoclonal antibody targeting CD47 for treating various types of blood cancers. But the drug has repeatedly hit speed breakers. Over the weekend, at the European Hematology Association meeting, Gilead unveiled additional data from the halted trials. In Phase 3 trial ENHANCE, 539 patients with high-risk myelodysplastic syndromes received either magrolimab and azacitidine (standard treatment) or placebo plus standard treatment. More magrolimab + azacitidine arm patients discontinued treatment due to adverse events versus the placebo ...